Shirley V Wang (Shirley Wang)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 53

Top Venues

Pharmacoepidemiology and drug safety

Clinical pharmacology and therapeutics

BMJ medicine

Annals of internal medicine

Brown University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Brown University Aug 01 2007 - Jan 01 2011

United States

PHD

Publications

Leah Zoe Gibson Rand, Sarah McGraw, Junyi Wang, Steven Woloshin, Shirley V Wang, Jonathan J Darrow, Aaron S Kesselheim
Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?" Journal of the American Geriatrics Society 72 (9) (2024)
John Tazare, Shirley V Wang, Rosa Gini, Daniel Prieto Alhambra, Peter Arlett, Daniel R Morales Leaver, Caroline Morton, John Logie, Jennifer Popovic, Katherine Donegan, Sebastian G Schneeweiss, Ian Douglas, Anna Schultze
Sharing Is Caring? International Society for Pharmacoepidemiology Review and Recommendations for Sharing Programming Code. Pharmacoepidemiology and drug safety 33 (9) (2024)
Shirley V Wang, Kueiyu Joshua Lin, Sebastian G Schneeweiss
Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors. Pharmacoepidemiology and drug safety 33 (5) (2024)
Rachel Heyard, Leonhard Held, Sebastian G Schneeweiss, Shirley V Wang
Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data. BMJ medicine 3 (1) (2024)
Janick G Weberpals, Shirley V Wang
The FAIRification of research in real-world evidence: A practical introduction to reproducible analytic workflows using Git and R. Pharmacoepidemiology and drug safety 33 (1) (2024)
Rachel Heyard, Leonhard Held, Sebastian G Schneeweiss, Shirley V Wang
Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data. BMJ medicine 3 (1) (2024)
Rachel Heyard, Leonhard Held, Sebastian G Schneeweiss, Shirley V Wang
Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data. BMJ medicine 3 (1) (2024)
Samy Suissa, Sebastian Schneeweiss, William B Feldman, Helen Tesfaye, Shirley V Wang
Emulating Randomized Trials by Observational Database Studies: The RCT-DUPLICATE Initiative in COPD and Asthma. American journal of epidemiology (2024)
Rachel Heyard, Leonhard Held, Sebastian G Schneeweiss, Shirley V Wang
Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data. BMJ medicine 3 (1) (2024)
Shirley V Wang, Kueiyu Joshua Lin, Sebastian G Schneeweiss
Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors. Pharmacoepidemiology and drug safety 33 (5) (2024)
Shirley V Wang, Kueiyu Joshua Lin, Sebastian G Schneeweiss
Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors. Pharmacoepidemiology and drug safety 33 (5) (2024)
Janick G Weberpals, Shirley V Wang
The FAIRification of research in real-world evidence: A practical introduction to reproducible analytic workflows using Git and R. Pharmacoepidemiology and drug safety (2024)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine 177 (1) (2024)
Janick G Weberpals, Shirley V Wang
The FAIRification of research in real-world evidence: A practical introduction to reproducible analytic workflows using Git and R. Pharmacoepidemiology and drug safety 33 (1) (2024)
Massimiliano Russo, Shirley V Wang
An open-source implementation of tree-based scan statistics. Pharmacoepidemiology and drug safety 33 (3) (2024)
Loreen Straub, Shirley V Wang, Sonia Hernandez-Diaz, Kathryn J Gray Guseh, Seanna M Vine, Massimiliano Russo, Leena Mittal, Brian T Bateman, Yanmin Zhu, Krista F Huybrechts
Hierarchical Clustering Analysis to Inform Classification of Congenital Malformations for Surveillance of Medication Safety in Pregnancy. American journal of epidemiology (2024)
Janick G Weberpals, Shirley V Wang
External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future Directions. Clinical pharmacology and therapeutics (2024)
Priyanka Anand, Elvira D'Andrea, William Feldman, Shirley V Wang, Jun Liu, Gregory Brill, Elyse DiCesare, Kueiyu Joshua Lin
A Dynamic Prognostic Model for Identifying Vulnerable COVID-19 Patients at High Risk of Rapid Deterioration. Pharmacoepidemiology and drug safety 33 (8) (2024)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine 177 (1) (2024)
Leah Zoe Gibson Rand, Sarah McGraw, Junyi Wang, Steven Woloshin, Shirley V Wang, Jonathan J Darrow, Aaron S Kesselheim
Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?" Journal of the American Geriatrics Society (2024)
Leah Zoe Gibson Rand, Sarah McGraw, Junyi Wang, Steven Woloshin, Shirley V Wang, Jonathan J Darrow, Aaron S Kesselheim
Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?" Journal of the American Geriatrics Society 72 (9) (2024)
Julien Kirchgesner, Shirley V Wang, Sebastian G Schneeweiss
Strengthening Real-World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach. Pharmacoepidemiology and drug safety 33 (9) (2024)
Shirley V Wang, Kueiyu Joshua Lin, Sebastian G Schneeweiss
Emulation of randomized trials of direct oral anticoagulants with claims data and implications for new Factor XI inhibitors. Pharmacoepidemiology and drug safety 33 (5) (2024)
Phyo Than Htoo, Robert J Glynn, Shirley V Wang, Julie M Paik, Sebastian G Schneeweiss, Alexander Muir Walker, Elisabetta Patorno
Stratified analysis in comparative effectiveness studies that emulate randomized trials. Pharmacoepidemiology and drug safety (2023)
Rachel Heyard, Leonhard Held, Sebastian G Schneeweiss, Shirley V Wang
Design differences explain variation in results between randomized trials and their non-randomized emulations. medRxiv : the preprint server for health sciences (2023)
HoJin Shin, Shirley V Wang, Dae Hyun Kim, Ethan Alt, Mufaddal Mahesri, Lily G Bessette, Sebastian G Schneeweiss, Mehdi Najafzadeh
Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results. Clinical pharmacology and therapeutics (2023)
Mehdi NajafZadeh, HoJin Shin, Sebastian G Schneeweiss, Shirley V Wang, Scott D Solomon, Orly Vardeny, Elisabetta Patorno
High-dose vs. standard-dose influenza vaccine and cardiopulmonary hospitalization or mortality: emulating the INVESTED trial using insurance claims data. Clinical pharmacology and therapeutics (2023)
Yinzhu Jin, Janick G Weberpals, Shirley V Wang, Rishi J Desai, David Merola, Kueiyu Joshua Lin
The Impact of Longitudinal Data-Completeness of Electronic Health Record Data on the Prediction Performance of Clinical Risk Scores. Clinical pharmacology and therapeutics (2023)
Priyanka Anand, Yichi Zhang, David Merola, Yinzhu Jin, Shirley V Wang, Joyce Lii, Jun Liu, Kueiyu Joshua Lin
Comparison of EHR data-completeness in patients with different types of medical insurance coverage in the United States. Clinical pharmacology and therapeutics (2023)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine (2023)
Shirley V Wang, Sushama Kattinakere Sreedhara, Sebastian Schneeweiss, null null
Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. Nature communications 13 (1) (2022)
Shirley V Wang, Jesper Hallas, William Crown, Peter Arlett, Darren M Ashcroft, Eric I Benchimol, Marc L Berger, Gracy Crane, Wim Goettsch, Wei Hua, Shaum Kabadi, David M Kern, Xavier Kurz, Sinead Langan, Takahiro Nonaka, Lucinda Orsini, Susanna Perez-Gutthann, Simone Pinheiro, Nicole L Pratt, Sebastian G Schneeweiss, Massoud Toussi, Rebecca J Williams
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. Pharmacoepidemiology and drug safety (2022)
David Merola, Ulka Campbell, Nileesa Gautam, Alexa Rubens, Sebastian G Schneeweiss, Shirley V Wang, Gillis Carrigan, Victoria Chia, Osayi E Akinbosoye, Simone Pinheiro, Amanda Bruno, Xiaolong Jiao, Mark D Stewart, Rachele Hendricks-Sturrup, Carla Rodriguez-Watson, Sajan Khosla, Yiduo Zhang, Mothaffar Rimawi, Jenny Huang, Aliki Taylor, Lauren Becnel, Lynn McRoy, Joy Eckert, Benjamin Taylor
The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology. Clinical pharmacology and therapeutics (2022)
Nicolle M Gatto, Shirley V Wang, William Murk, Pattra Mattox, M Alan Brookhart, Andrew Bate, Sebastian G Schneeweiss, Jeremy A Rassen
Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting. Pharmacoepidemiology and drug safety 31 (11) (2022)
Kueiyu Joshua Lin, Elvira D'Andrea, Rishi J Desai, Joshua J Gagne, Jun Liu, Shirley V Wang
Prospective validation of a dynamic prognostic model for identifying COVID-19 patients at high risk of rapid deterioration. Pharmacoepidemiology and drug safety (2022)
Shirley V Wang, Sebastian G Schneeweiss
A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data. Clinical epidemiology 14 (2022)
John Tazare, Richard Wyss, Jessica M Franklin, Liam Smeeth, Stephen J W Evans, Shirley V Wang, Sebastian G Schneeweiss, Ian J Douglas, Joshua J Gagne, Elizabeth J Williamson
Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. Pharmacoepidemiology and drug safety 31 (4) (2022)
Lars Christian Lund, Nina Sahlertz Kristiansen, Shirley V Wang
Online tool to create publication ready graphical depictions of longitudinal study design implemented in healthcare databases. Pharmacoepidemiology and drug safety 30 (7) (2021)
Shirley V Wang, Kristina Stefanini, Edwin Lewis, Sophia R Newcomer, Bruce Fireman, Matthew F Daley, Jason M Glanz, Jonathan Duffy, Eric Weintraub, Martin Kulldorff
Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event. Drug safety 43 (10) (2021)
Rishi J Desai, Michael E Matheny, Kevin Johnson, Keith Marsolo, Lesley H Curtis, Jennifer C Nelson, Patrick J Heagerty, Judith C Maro, Jeffrey S Brown, Sengwee Toh, Michael Nguyen, Robert Ball, Gerald Dal Pan, Shirley V Wang, Joshua J Gagne, Sebastian Schneeweiss
Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. NPJ digital medicine 4 (1) (2021)
Suzanne M Cadarette, Malcolm Maclure, Joseph A Chris Delaney, Heather J Whitaker, Kaleen N Hayes, Shirley V Wang, Mina Tadrous, Joshua J Gagne, Giulia P Consiglio, Nina Sahlertz Kristiansen
Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiology and drug safety 30 (6) (2021)
Shirley V Wang, Simone Pinheiro, Wei Hua, Peter Arlett, Yoshiaki Uyama, Jesse A Berlin, Dorothee B Bartels, Kristijan H Kahler, Lily G Bessette, Sebastian Schneeweiss
STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ (Clinical research ed.) 372 (2021)
Katsiaryna Bykov, Shirley V Wang, Nina Sahlertz Kristiansen, Jesper Hallas, Malcolm Maclure, Joshua J Gagne
Bias in case-crossover studies of medications due to persistent use: A simulation study. Pharmacoepidemiology and drug safety 29 (9) (2020)
Shirley V Wang, Olga V Patterson, Joshua J Gagne, Jeffrey S Brown, Robert Ball, Pall Jonsson, Adam Wright, Li Zhou, Wim Goettsch, Andrew Bate
Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety. Drug safety 42 (11) (2020)
Moa P Lee, Robert J Glynn, Sebastian G Schneeweiss, Kueiyu Joshua Lin, Elisabetta Patorno, Julie Barberio, Raisa Levin, Thomas Evers, Shirley V Wang, Rishi J Desai
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clinical epidemiology 12 (2020)
Lucinda S Orsini, Brigitta Monz, C Daniel Mullins, David Van Brunt, Gregory Daniel, Hans-Georg Eichler, Jennifer Graff, John Guerino, Marc Berger, Nirosha M Lederer, Pall Jonsson, Sebastian Schneeweiss, Shirley V Wang, William Crown, Wim Goettsch, Richard J Willke
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiology and drug safety 29 (11) (2020)
Rishi J Desai, Richard Wyss, Younathan Abdia, Sengwee Toh, Margaret Johnson, Hana Lee, Sara Karami, Jacqueline M Major, Michael Nguyen, Shirley V Wang, Jessica M Franklin, Joshua J Gagne
Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching-A plasmode simulation study. Pharmacoepidemiology and drug safety 28 (6) (2019)
Shirley V Wang, James R Rogers, Yinzhu Jin, David DeiCicchi, Sara Dejene, Jean M Connors, David W Bates, Robert J Glynn, Michael A Fischer
Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. BMJ quality & safety 28 (10) (2019)
Shirley V Wang
Commentary in response to Carrigan et al: "An Evaluation of the Impact of Missing Deaths on Overall Survival Analyses of Advanced Non-small Cell Lung Cancer Patients Conducted in an Electronic Health Records Database". Pharmacoepidemiology and drug safety 28 (5) (2019)
Ryan M Carnahan, Jennifer L Kuntz, Shirley V Wang, Candace Fuller, Joshua J Gagne, Charles E Leonard, Sean Hennessy, Tamra Meyer, Patrick Archdeacon, Chih-Ying Chen, Catherine A Panozzo, Sengwee Toh, Hannah Katcoff, Tiffany Woodworth, Aarthi Iyer, Sophia Axtman, Elizabeth A Chrischilles
Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection. Pharmacoepidemiology and drug safety 27 (7) (2018)
Shirley V Wang, Sebastian Schneeweiss, Marc L Berger, Jeffrey Brown, Frank de Vries, Ian Douglas, Joshua J Gagne, Rosa Gini, Olaf Klungel, C Daniel Mullins, Michael D Nguyen, Jeremy A Rassen, Liam Smeeth, Miriam Sturkenboom, null null
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and drug safety 26 (9) (2018)
Shirley V Wang, Martin Kulldorff, Robert J Glynn, Joshua J Gagne, Jesper Hallas, Kenneth J Rothman, Sebastian G Schneeweiss, Alexander Muir Walker
Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiology and drug safety 27 (6) (2018)
Shirley V Wang, Abdurrahman Abdurrob, Julia Spoendlin, Edwin Lewis, Sophia R Newcomer, Bruce Fireman, Matthew F Daley, Jason M Glanz, Jonathan Duffy, Eric S Weintraub, Martin Kulldorff
Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines. Pharmacoepidemiology and drug safety 27 (4) (2018)

Shirley V Wang.css-eqlu8i{font-size:small;padding-left:4px;} (Shirley Wang)

Publication Activity (10 Years)

Top Topics

Top Venues

Shirley V Wang (Shirley Wang)